Back to top
more

AngioDynamics (ANGO)

(Real Time Quote from BATS)

$7.45 USD

7.45
69,973

-0.03 (-0.40%)

Updated Jul 24, 2024 10:28 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (100 out of 250)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

AngioDynamics (ANGO) Advances But Underperforms Market: Key Facts

In the closing of the recent trading day, AngioDynamics (ANGO) stood at $6.21, denoting a +0.65% change from the preceding trading day.

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

AngioDynamics (ANGO) Q1 Earnings and Revenues Top Estimates

AngioDynamics (ANGO) registers strong revenue growth in the Med Tech business in first-quarter fiscal 2024.

AngioDynamics (ANGO) Reports Q1 Loss, Tops Revenue Estimates

AngioDynamics (ANGO) delivered earnings and revenue surprises of 14.29% and 1.32%, respectively, for the quarter ended August 2023. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate AngioDynamics (ANGO) to Report a Decline in Earnings: What to Look Out for

AngioDynamics (ANGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AngioDynamics (ANGO) Dips More Than Broader Markets: What You Should Know

AngioDynamics (ANGO) closed at $7.02 in the latest trading session, marking a -0.71% move from the prior day.

Avid Bioservices (CDMO) Reports Break-Even Earnings for Q1

Avid Bioservices (CDMO) delivered earnings and revenue surprises of 100% and 10.96%, respectively, for the quarter ended July 2023. Do the numbers hold clues to what lies ahead for the stock?

AngioDynamics (ANGO) Outpaces Stock Market Gains: What You Should Know

In the latest trading session, AngioDynamics (ANGO) closed at $8.15, marking a +1.88% move from the previous day.

AngioDynamics (ANGO) Stock Sinks As Market Gains: What You Should Know

AngioDynamics (ANGO) closed the most recent trading day at $8.76, moving -1.35% from the previous trading session.

AngioDynamics (ANGO) Flat As Market Sinks: What You Should Know

AngioDynamics (ANGO) closed at $8.58 in the latest trading session, marking no change from the prior day.

AngioDynamics' (ANGO) New FDA Recognition to Boost Treatment

The FDA's grant of the Breakthrough Device designation for AngioDynamics' (ANGO) AngioVac is likely to remove thrombus and embolic material and minimize blood loss via blood recirculation.

AngioDynamics (ANGO) Gains As Market Dips: What You Should Know

In the latest trading session, AngioDynamics (ANGO) closed at $8.34, marking a +1.46% move from the previous day.

AngioDynamics (ANGO) Q4 Earnings Lag Estimates, Revenues Top

AngioDynamics (ANGO) registers strong revenue growth in the Med Tech and Med Device businesses in fourth-quarter fiscal 2023.

AngioDynamics (ANGO) Lags Q4 Earnings Estimates

AngioDynamics (ANGO) delivered earnings and revenue surprises of -33.33% and 0.37%, respectively, for the quarter ended May 2023. Do the numbers hold clues to what lies ahead for the stock?

AngioDynamics (ANGO) to Report Q4 Earnings: What's in the Cards?

AngioDynamics' (ANGO) fiscal fourth quarter's top line is likely to have been driven by strong demand for its products.

AngioDynamics (ANGO) Reports Next Week: Wall Street Expects Earnings Growth

AngioDynamics (ANGO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Cintas (CTAS) to Post Q4 Earnings: Will Cost Woes Mar Results?

Cintas' (CTAS) Q4 performance is likely to have been hurt by rising costs. However, higher volumes and prices within the Uniform Rental and Facility Services unit are likely to have aided the same.

Simulations Plus (SLP) to Report Q3 Earnings: What's in Store?

Simulations Plus' (SLP) third-quarter performance is likely to have gained from the healthy adoption of its solutions across various verticals amid continued macroeconomic weakness.

Are Options Traders Betting on a Big Move in AngioDynamics (ANGO) Stock?

Investors need to pay close attention to AngioDynamics (ANGO) stock based on the movements in the options market lately.

Merit Medical (MMSI) Expands Suite via Buyouts, Revises FY23 View

Merit Medical's (MMSI) latest addition to its portfolio is expected to significantly enhance patient outcomes.

New Strong Sell Stocks for May 18th

ANGO, FPAY and BRDG have been added to the Zacks Rank #5 (Strong Sell) List on May 18, 2023.

Zacks.com featured highlights include Dutch Bros, Chegg, Impinj and AngioDynamics

Dutch Bros, Chegg, Impinj and AngioDynamics are part of the Zacks Screen of the Week article.

Is the Options Market Predicting a Spike in AngioDynamics (ANGO) Stock?

Investors need to pay close attention to AngioDynamics (ANGO) stock based on the movements in the options market lately.

Lavina Shahu headshot

Sell These 4 Toxic Stocks to Prevent Portfolio Losses

The basic understanding of toxic stocks can help investors avoid huge losses and derive maximum benefit from their portfolios. Some toxic stocks that investors may consider dumping are BROS, CHGG, PI and ANGO.

Zacks.com featured highlights include AngioDynamics, Definitive Healthcare, Casella Waste Systems and Enviva

AngioDynamics, Definitive Healthcare, Casella Waste Systems and Enviva are part of the Zacks Screen of the Week article.